Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vytorin vs Rosuvastatin in Primary Hypercholesterolemia
NCT00090298Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Apr 2004
- Primary completion
- Dec 2004
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
01
Overview
Phase 3, randomised, double-blind trial of Vytorin in hypercholesterolemia (2 arms), sponsored by Organon & Co. Primary endpoint: LDL-C lowering efficacy at 6 weeks. Started Apr 2004; status: completed.
02
Drugs
Vytorin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00090298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090298.